1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Ophthalmology
  6. NPI Profile
  7. Prescriptions 1811907710

DR. STEVEN A TEICH MD
Prescription History 1811907710
Ophthalmology - Retina Specialist in New York, NY

NPI Status: Active since August 09, 2006

Contact Information

20 E 68TH ST
GROUND FL - BOX P1
NEW YORK, NY
ZIP 10065
Phone: (212) 734-9170
Fax: (212) 734-9061

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STEVEN A TEICH MD, an active Retina Specialist specialist practicing in New York, NY. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 87 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 31 claims alone.

Medication Index

E
L
P
T
No matching medications currently found on file.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 234
NY State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills55.9
Peer Average Days Supply938
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.4% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $268.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.69

State Avg Cost Per Claim

$19.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 31
30-Day Fills 54.2
Days Supply 1,513
NY State Average Benchmarks
Peer Average Claims149.0
Peer Average 30-Day Fills254.5
Peer Average Days Supply7,268
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.2% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $524.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.91

State Avg Cost Per Claim

$20.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Polymyxin B Sul-Trimethoprim

Generic Formulation: Polymyxin B Sulf/TrimethoprimSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 14
30-Day Fills 18.4
Days Supply 472
NY State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills46.8
Peer Average Days Supply1,176
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.2% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $127.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.12

State Avg Cost Per Claim

$8.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat bacterial infections (such as blepharitis, conjunctivitis) of the eye. It contains 2 antibiotics. Polymyxin B works by killing the bacteria. Trimethoprim works by stopping the growth of the bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 19
30-Day Fills 31.2
Days Supply 936
NY State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills139.2
Peer Average Days Supply4,099
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,424.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$180.22

State Avg Cost Per Claim

$38.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. STEVEN A TEICH MD provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Retina Specialist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.